NCT02008136

Brief Summary

This protocol is a prospective, open label, pilot study examining the utility of three established pain questionnaires (the Visual Analogue Scale (VAS), Neck Disability Index (NDI), the Oswestry Low Back Pain Questionnaire and two novel pain scale devised by the PI) as well as their relationship to three novel quantitative tools to measure the effect of botulinum toxin injections for neck pain and back pain. The three novel methods for measuring neurotoxin effect are: muscle twitch patterns using surface electromyography (sEMG), cervical and lumbar range of motion using a neck and low back inclinometer, and skin surface temperature readings using an infrared imaging camera.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Mar 2016

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 27, 2013

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 11, 2013

Completed
2.2 years until next milestone

Study Start

First participant enrolled

March 1, 2016

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

December 7, 2017

Status Verified

December 1, 2017

Enrollment Period

2.4 years

First QC Date

November 27, 2013

Last Update Submit

December 5, 2017

Conditions

Keywords

myofascial painmuscle spasmbotulinum toxincervicalgialumbagolow back pain

Outcome Measures

Primary Outcomes (1)

  • Lumbar Pain Rating Scale

    This is an 8 point rating scale for low back pain

    3 months

Secondary Outcomes (5)

  • digital thermography

    3 months

  • VAS score

    3 months

  • Oswestry Lumbar Disability Scale

    3 months

  • Cervical and Lumbar Range of Motion

    3 months

  • surface EMG (sEMG)

    3 months

Study Arms (1)

botulinum toxin injected

EXPERIMENTAL

Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)

Drug: Botulinum Toxins

Interventions

intramuscular injections

Also known as: Botox, Myobloc
botulinum toxin injected

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Veterans with chronic neck or back pain for at least 6 months.
  • No botulinum toxin injections in the last 6 months.

You may not qualify if:

  • Non-muscular neck or back pain
  • Signs or symptoms of nerve root or spinal cord injury
  • History of adverse events associated with botulinum toxin injections
  • Major neurological disorder
  • recent stroke
  • myasthenia gravis
  • muscular dystrophy
  • myotonic dystrophy
  • amyotrophic lateral sclerosis
  • Unstable cardiac or pulmonary disease
  • Pregnancy
  • Severe psychiatric illness, dementia or delirium
  • Excessive obesity
  • Severe spinal curvature (i.e. severe scoliosis or severe kyphosis)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Connecticut Healthcare Services

West Haven, Connecticut, 06516, United States

RECRUITING

MeSH Terms

Conditions

Neck PainLow Back PainSpasm

Interventions

Botulinum ToxinsBotulinum Toxins, Type ArimabotulinumtoxinB

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsBack PainNeuromuscular ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

MetalloendopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesMetalloproteasesBacterial ProteinsProteinsAmino Acids, Peptides, and ProteinsBacterial ToxinsToxins, BiologicalBiological Factors

Study Officials

  • Hajime A Tokuno, MD

    VA Connecticut

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hajime A Tokuno, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 27, 2013

First Posted

December 11, 2013

Study Start

March 1, 2016

Primary Completion

August 1, 2018

Study Completion

December 1, 2018

Last Updated

December 7, 2017

Record last verified: 2017-12

Data Sharing

IPD Sharing
Will not share

Locations